Clinical and demographic characteristics of patients with lipitension: results from the largest retrospective emr study from india

Objective: Common end-organ manifestations of hypertension and dyslipidemia predispose patients to develop cardiovascular diseases (CVD). The data on coexistent hypertension and dyslipidemia (lipitension) in India is scarce. In patients with lipitension CVD risk is amplified, therefore necessitating better understanding of their current clinical characteristics and treatment gaps. Design and method: This was an EMR based, retrospective, multicenter, cross sectional, database study to evaluate the demographic and clinical profile of adult patients with age more than 18 years having coexistent hypertension and dyslipidemia in India. Data of patients with Type 1 Diabetes Mellitus, Familial Hypercholesterolemia and pregnant females were excluded. Results: Data of 6722173 (6.7 million approx.) patients with age more than or equal to 18 years registered in EMR from January 2021 to December 2021 was extracted from the EMR database. Out of these patients, 38343 cases (0.57%) were found to have lipitension. Mean age was noted to be 54.71 years and 55.5% of them were males. The mean BMI of the patients was 28.3 kg/m 2 , and 76% of patients had an above normal BMI (>24.99). The mean SBP and DBP in mmHg were noted to be 139.98 and 85.47, respectively. Only 8% and 18.7% of patients had a normal SBP and normal DBP, respectively. The mean in mg/dl (% non-optimal control) of LDL, total cholesterol, triglycerides and VLDL was 124.2 (89.2), 195.1 (46.6), 176.8 (56.1) and 27.4 (40.7), respectively. The mean HDL was 46.69 mg/dl and optimal HDL of >60 mg/dl was noted in 11% of patients. Beta blockers (20.2%) and combination of anti-hypertensive with diuretics (14.5%) were most used for hypertension. Statins in combination with other medicines were used in 33.3% of patients and 41.7% were on statins alone. Conclusions: The findings suggests that control of lipitension in India is inadequate despite current therapy being offered, this puts patients at a higher risk for early-onset CVD. Hence, there is an urgent need to create awareness and optimize management of lipitension.